scholarly journals Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan

2021 ◽  
Vol 12 ◽  
Author(s):  
Yu-Tung Lai ◽  
Chung-Yu Chen ◽  
Ming-Jong Bair
Keyword(s):  
Irritable Bowel Syndrome ◽  
Peptic Ulcer ◽  
Clinical Features ◽  
Annual Incidence ◽  
Prescribing Patterns ◽  
Symptom Duration ◽  
Research Database ◽  
Prescribing Pattern ◽  
Gi Endoscopy ◽  
Irritable Bowel

Background: Understanding the prescribing patterns could better inform irritable bowel syndrome (IBS) management and health policy. However, there is no study on prescribing patterns of IBS in Taiwan. This study was conducted to evaluate the epidemiology, clinical features, and prescribing patterns of IBS in Taiwan.Methods: This population-based cross-sectional study was performed by retrieving claim data from National Health Insurance Research Database (NHIRD) between 2011 and 2018 in Taiwan. Patients who were diagnosed with IBS during 2012–2018 and more than 20 years old were included. The annual incidence and prevalence of IBS were estimated. The characteristics and prescribing pattern were evaluated among IBS population. The population with IBS were followed from index date until 1 year after or death.Results: A total of 1691596 patients diagnosed with IBS were identified from 2012 to 2018. The average annual incidence and prevalence of IBS in Taiwan were calculated as 106.54 and 181.75 per 10,000 population. The incidence and prevalence showed a decreasing trend from 2012 to 2018. Hypertension, dyslipidemia, chronic liver disease, peptic ulcer, gastroesophageal reflux disease (GERD), anxiety, and sleep disorder were the prevalent comorbidities in IBS population. At 1 year after IBS diagnosis, the rates of peptic ulcer and GERD; the utilizations of abdominal ultrasonography, upper gastrointestinal (GI) endoscopy, and lower GI endoscopy; the prescribing rate of propulsives, simethicone, antacids, H2-blockers, and proton pump inhibitors significantly increased. Approximately 70% of participants received IBS-related treatment. Antispasmodics was the most frequently prescribed medication class, followed by laxatives and antidiarrheals. Only 48.58% of patients made return visit for IBS at 1 year after IBS diagnosis. Consequently, the proportion of consultation for IBS and the prescribing rates of all medications were decreased considerably after IBS diagnosis.Conclusion: The incidence and prevalence of IBS showed a decreasing trend from 2012 to 2018. More than two-third of patients received treatment for IBS. Antispasmodics was widely used for IBS management. However, patients may have a short symptom duration or receive a short course of IBS-related treatment in Taiwan. These findings provided the whole picture of the epidemiology and prescribing pattern of the IBS population in Taiwan.

Peptic Ulcer, Non-Ulcer Dyspepsia and Irritable Bowel Syndrome in the Netherlands and Japan

1993 ◽  
Vol 28 (sup200) ◽  
pp. 33-41 ◽  
Author(s):  
R. J. Schlemper ◽  
S. D. J. Van Der Werf ◽  
J. P. Vandenbroucke ◽  
I. Biemond ◽  
C. B. H. W. Lamers
Keyword(s):  
Irritable Bowel Syndrome ◽  
Peptic Ulcer ◽  
The Netherlands ◽  
Non Ulcer Dyspepsia ◽  
Irritable Bowel

scholarly journals Helicobacter Pylori as a Risk Factor for Post Infectious Irritable Bowel Syndrome

2022 ◽  
pp. 1-3
Author(s):  
Essamaddin Ahmed Abdelhamid Ibrahim ◽  
Keyword(s):  
Helicobacter Pylori ◽  
Irritable Bowel Syndrome ◽  
Peptic Ulcer ◽  
Triple Therapy ◽  
Analytical Study ◽  
Ulcer Disease ◽  
Standard Triple Therapy ◽  
Irritable Bowel ◽  
Post Infectious ◽  
Structured Questionnaire

Backgrounds: Helicobacter Pylori is a common pathogen leading cause of peptic ulcer disease. Several studies linked Helicobacter Pylori infection and the development of irritable bowel syndrome. Aims: We investigated the effectiveness of standard triple therapy and the association between H.Pylori infection and the development of post infectious irritable bowel syndrome. Materials and methods: Prospective analytical study was conducted and we appointed 200 H.Pylori positive patients, they consented and subjected to structured questionnaire and received standard triple therapy (14 days course of proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole). After three months all patients re-evaluated regarding their symptoms and tested for eradication. Additionally we evaluated the association between H.Pylori infection and irritable bowel syndrome

A Clinical study of Erandamooladi Niruha Basti in the management of Grahani w.s.r. to Irritable Bowel Syndrome

2017 ◽  
Vol 2 (06) ◽  
Author(s):  
Mallikarjun . ◽  
Channabasavanna B. M.
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Study ◽  
Clinical Features ◽  
Western Medicine ◽  
Digestive System ◽  
Classical Text ◽  
Irritable Bowel ◽  
Special Case

Grahani Roga described in classical text books of Ayurveda represents a group of disorders of digestive system caused by impairment of Agni. Grahani is such a disorder, where in its significance is emphasized by its inclusion among Ashtamaha Gadas. The cardinal features of Grahani explained in the clasical text books of Ayurveda, have at most similarities with the clinical features of Irritable Bowel Syndrome (IBS) explained in western medicine. A total of 15 patients were selected and treated with Erandamooladi Niruha Basti and Changeryadi Ghrita Anuvasana Basti, was given in Yoga Basti pattern according to inclusive and exclusive criteria. Special case proforma was designed and parameters were assessed. It showed highly significant results in all the parameters at the level of p less than 0.01.

scholarly journals Risk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan

2020 ◽  
Vol 17 (10) ◽  
pp. 3737
Author(s):  
Chia-Ming Liang ◽  
Chih-Hsiung Hsu ◽  
Chi-Hsiang Chung ◽  
Chao-Yang Chen ◽  
Lin-Yin Wang ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Irritable Bowel Syndrome ◽  
Cohort Study ◽  
Cumulative Incidence ◽  
Eradication Therapy ◽  
Research Database ◽  
Increased Risk ◽  
Comparison Cohort ◽  
H Pylori ◽  
Irritable Bowel

Background: The association between Helicobacter pylori (H. pylori) infection and the risk of developing irritable bowel syndrome (IBS) has yet to be investigated; thus, we conducted this nationwide cohort study to examine the association in patients from Taiwan. Methods: A total of approximately 2669 individuals with newly diagnosed H. pylori infection and 10,676 age- and sex-matched patients without a diagnosis of H. pylori infection from 2000 to 2013 were identified from Taiwan’s National Health Insurance Research Database. The Kaplan–Meier method was used to determine the cumulative incidence of H. pylori infection in each cohort. Whether the patient underwent H. pylori eradication therapy was also determined. Results: The cumulative incidence of IBS was higher in the H. pylori-infected cohort than in the comparison cohort (log-rank test, p < 0.001). After adjustment for potential confounders, H. pylori infection was associated with a significantly increased risk of IBS (adjusted hazard ratio (aHR) 3.108, p < 0.001). In addition, the H. pylori-infected cohort who did not receive eradication therapy had a higher risk of IBS than the non-H. pylori-infected cohort (adjusted HR 4.16, p < 0.001). The H. pylori-infected cohort who received eradication therapy had a lower risk of IBS than the comparison cohort (adjusted HR 0.464, p = 0.037). Conclusions: Based on a retrospective follow-up, nationwide study in Taiwan, H. pylori infection was associated with an increased risk of IBS; however, aggressive H. pylori infection eradication therapy can also reduce the risk of IBS. Further underlying biological mechanistic research is needed.

Sign in / Sign up

Export Citation Format

Share Document